Eupraxia Pharmaceuticals Announces Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
Histological scores and symptom scores continue to improve as EP-104GI dose, and area of esophageal coverage, increase Cohort 6 showed the greatest symptom relief scores ("SDI") of all cohorts to date at 12 weeks Cohort 6 had the greatest magnitude and percentage change in tissue health scores ("EoEHSS") of any cohort to date at 12 weeks Cohort 6 saw the greatest reduction in Peak Eosinophil Count ("PEC") of any cohort to date Cohort 5 demonstrated the greatest symptom score reduction (SDI) seen to date at ...